Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ, Christos P, Sparano JA, Matulich D, Kaubish A, Siegel A, Sung M, Ward MM, Hamel N, Espinoza-Delgado I, Yen Y, Lane ME. Ocean AJ, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2011 Aug;68(2):379-88. doi: 10.1007/s00280-010-1481-z. Epub 2010 Oct 28. Cancer Chemother Pharmacol. 2011. PMID: 20981545 Free PMC article. Clinical Trial.
Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.
Newman EM, Carroll M, Akman SA, Chow W, Coluzzi P, Hamasaki V, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata S, Somlo G, Tetef M, Yen Y, Ahn CW, Doroshow JH. Newman EM, et al. Among authors: yen y. Cancer Chemother Pharmacol. 1997;39(3):254-8. doi: 10.1007/s002800050569. Cancer Chemother Pharmacol. 1997. PMID: 8996529 Clinical Trial.
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Yen Y, et al. Cancer Chemother Pharmacol. 2002 Nov;50(5):353-9. doi: 10.1007/s00280-002-0492-9. Epub 2002 Sep 12. Cancer Chemother Pharmacol. 2002. PMID: 12439592 Clinical Trial.
Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies.
Morgan RJ Jr, Newman EM, Sowers L, Scanlon K, Harrison J, Akman S, Leong L, Margolin K, Niland J, Raschko J, Somlo G, Carroll M, Chow W, Tetef M, Hamasaki V, Yen Y, Doroshow JH. Morgan RJ Jr, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2003 Jun;51(6):459-64. doi: 10.1007/s00280-003-0605-0. Epub 2003 Apr 15. Cancer Chemother Pharmacol. 2003. PMID: 12695856 Clinical Trial.
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. Shibata S, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2007 Mar;59(4):549-57. doi: 10.1007/s00280-006-0297-3. Epub 2006 Oct 19. Cancer Chemother Pharmacol. 2007. PMID: 17051371 Clinical Trial.
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. Ramanathan RK, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2009 Sep;64(4):777-83. doi: 10.1007/s00280-009-0927-7. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169683 Clinical Trial.
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM. Shibata SI, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2009 Nov;64(6):1149-55. doi: 10.1007/s00280-009-0977-x. Epub 2009 Mar 26. Cancer Chemother Pharmacol. 2009. PMID: 19322566 Free PMC article. Clinical Trial.
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH. Morgan RJ, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2010 Oct;66(5):927-33. doi: 10.1007/s00280-010-1242-z. Epub 2010 Jan 28. Cancer Chemother Pharmacol. 2010. PMID: 20107803 Free PMC article. Clinical Trial.
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ. Sridhar SS, et al. Among authors: yen y. Cancer Chemother Pharmacol. 2011 Apr;67(4):927-33. doi: 10.1007/s00280-010-1389-7. Epub 2010 Jul 3. Cancer Chemother Pharmacol. 2011. PMID: 20602233 Clinical Trial.
1,619 results